 |
|||||
|
|||||
|
|||||
|
|||||
|
|||||
The Journal of Neuroscience, April 20, 2005, 25(16):4169-4180; doi:10.1523/JNEUROSCI.0590-05.2005
Previous Article | Next Article
Neurobiology of Disease
Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease
Jeremy M. Van Raamsdonk,1,2 Jacqueline Pearson,1,2 Elizabeth J. Slow,1,2 Sazzad M. Hossain,1,2 Blair R. Leavitt,1,2 andMichael R. Hayden1,2 1Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, V6T 1Z3 Canada, and 2Centre for Molecular Medicine and Therapeutics, British Columbia Research Institute, Vancouver, British Columbia, V5Z 4H4 Canada
Huntington's disease (HD) is an adult-onset neurodegenerative disorder involving motor dysfunction, cognitive deficits, and psychiatric disturbances that result from underlying striatal and cortical dysfunction and neuropathology. The YAC128 mouse model of HD reproduces both the motor deficits and selective degeneration observed in the human disease. However, the presence of cognitive impairment in this model has not been determined. Here, we report mild cognitive deficits in YAC128 mice that precede motor onset and progressively worsen with age. Rotarod testing revealed a motor learning deficit at 2 months of age that progresses such that by 12 months of age, untrained YAC128 mice are unable to learn the rotarod task. Additional support for cognitive dysfunction is evident in a simple swimming test in which YAC128 mice take longer to find the platform than wild-type (WT) controls beginning at 8 months of age. YAC128 mice also have deficits in open-field habituation and in a swimming T-maze test at this age. Strikingly, in the reversal phase of the swimming T-maze test, YAC128 mice take twice as long as WT mice to locate the platform, indicating a difficulty in changing strategy. At 12 months of age, YAC128 mice show decreased prepulse inhibition and habituation to acoustic startle. The clear pattern of cognitive dysfunction in YAC128 mice is similar to the symptoms and progression of cognitive deficits in human HD and provides both the opportunity to examine the relationship between cognitive dysfunction, motor impairment, and neuropathology in HD and to assess whether potential therapies for HD can restore cognitive function.
Key words: Huntington's disease; cognition; behavior; mouse model; learning; memory
Received Dec 15, 2004; revised March 11, 2005; accepted March 15, 2005.
This article has been cited by other articles:
A. L. Southwell, J. Ko, and P. H. Patterson
Intrabody Gene Therapy Ameliorates Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models of Huntington's Disease
J. Neurosci., October 28, 2009; 29(43): 13589 - 13602.
[Abstract] [Full Text] [PDF]
J. Fan, C. M. Cowan, L. Y. J. Zhang, M. R. Hayden, and L. A. Raymond
Interaction of Postsynaptic Density Protein-95 with NMDA Receptors Influences Excitotoxicity in the Yeast Artificial Chromosome Mouse Model of Huntington's Disease
J. Neurosci., September 2, 2009; 29(35): 10928 - 10938.
[Abstract] [Full Text] [PDF]
M. A. Pouladi, R. K. Graham, J. M. Karasinska, Y. Xie, R. D. Santos, A. Petersen, and M. R. Hayden
Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin
Brain, April 1, 2009; 132(4): 919 - 932.
[Abstract] [Full Text] [PDF]
D. A. Simmons, C. S. Rex, L. Palmer, V. Pandyarajan, V. Fedulov, C. M. Gall, and G. Lynch
Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice
PNAS, March 24, 2009; 106(12): 4906 - 4911.
[Abstract] [Full Text] [PDF]
D. E. Ehrnhoefer, S. L. Butland, M. A. Pouladi, and M. R. Hayden
Mouse models of Huntington disease: variations on a theme
Dis. Model. Mech., March 1, 2009; 2(3-4): 123 - 129.
[Abstract] [Full Text] [PDF]
P. R. Joshi, N.-P. Wu, V. M. Andre, D. M. Cummings, C. Cepeda, J. A. Joyce, J. B. Carroll, B. R. Leavitt, M. R. Hayden, M. S. Levine, et al.
Age-Dependent Alterations of Corticostriatal Activity in the YAC128 Mouse Model of Huntington Disease
J. Neurosci., February 25, 2009; 29(8): 2414 - 2427.
[Abstract] [Full Text] [PDF]
R. K. Graham, M. A. Pouladi, P. Joshi, G. Lu, Y. Deng, N.-P. Wu, B. E. Figueroa, M. Metzler, V. M. Andre, E. J. Slow, et al.
Differential Susceptibility to Excitotoxic Stress in YAC128 Mouse Models of Huntington Disease between Initiation and Progression of Disease
J. Neurosci., February 18, 2009; 29(7): 2193 - 2204.
[Abstract] [Full Text] [PDF]
C. M. Cowan, M. M. Y. Fan, J. Fan, J. Shehadeh, L. Y. J. Zhang, R. K. Graham, M. R. Hayden, and L. A. Raymond
Polyglutamine-Modulated Striatal Calpain Activity in YAC Transgenic Huntington Disease Mouse Model: Impact on NMDA Receptor Function and Toxicity
J. Neurosci., November 26, 2008; 28(48): 12725 - 12735.
[Abstract] [Full Text] [PDF]
S. C. Warby, C. N. Doty, R. K. Graham, J. B. Carroll, Y.-Z. Yang, R. R. Singaraja, C. M. Overall, and M. R. Hayden
Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus
Hum. Mol. Genet., August 1, 2008; 17(15): 2390 - 2404.
[Abstract] [Full Text] [PDF]
A. J. Milnerwood and L. A. Raymond
Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load
J. Physiol., December 15, 2007; 585(3): 817 - 831.
[Abstract] [Full Text] [PDF]
H. B. Fernandes, K. G. Baimbridge, J. Church, M. R. Hayden, and L. A. Raymond
Mitochondrial Sensitivity and Altered Calcium Handling Underlie Enhanced NMDA-Induced Apoptosis in YAC128 Model of Huntington's Disease
J. Neurosci., December 12, 2007; 27(50): 13614 - 13623.
[Abstract] [Full Text] [PDF]
G. Lynch, E. A. Kramar, C. S. Rex, Y. Jia, D. Chappas, C. M. Gall, and D. A. Simmons
Brain-Derived Neurotrophic Factor Restores Synaptic Plasticity in a Knock-In Mouse Model of Huntington's Disease
J. Neurosci., April 18, 2007; 27(16): 4424 - 4434.
[Abstract] [Full Text] [PDF]
H. P. Nguyen, P. Kobbe, H. Rahne, T. Worpel, B. Jager, M. Stephan, R. Pabst, C. Holzmann, O. Riess, H. Korr, et al.
Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease
Hum. Mol. Genet., November 1, 2006; 15(21): 3177 - 3194.
[Abstract] [Full Text] [PDF]
G. L. Dunbar, M. I. Sandstrom, J. Rossignol, and L. Lescaudron
Neurotrophic Enhancers as Therapy for Behavioral Deficits in Rodent Models of Huntington's Disease: Use of Gangliosides, Substituted Pyrimidines, and Mesenchymal Stem Cells.
Behav Cogn Neurosci Rev, June 1, 2006; 5(2): 63 - 79.
[Abstract] [PDF]
J. M. Van Raamsdonk, W. T. Gibson, J. Pearson, Z. Murphy, G. Lu, B. R. Leavitt, and M. R. Hayden
Body weight is modulated by levels of full-length Huntingtin
Hum. Mol. Genet., May 1, 2006; 15(9): 1513 - 1523.
[Abstract] [Full Text] [PDF]
J. M. Van Raamsdonk, Z. Murphy, E. J. Slow, B. R. Leavitt, and M. R. Hayden
Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease
Hum. Mol. Genet., December 15, 2005; 14(24): 3823 - 3835.
[Abstract] [Full Text] [PDF]
E. J. Slow, R. K. Graham, A. P. Osmand, R. S. Devon, G. Lu, Y. Deng, J. Pearson, K. Vaid, N. Bissada, R. Wetzel, et al.
Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions
PNAS, August 9, 2005; 102(32): 11402 - 11407.
[Abstract] [Full Text] [PDF]
|
|
|
|
 |
|